Score! 'Good Pharma' ranking finds uptick in new drug data sharing and clinical trial transparency

Graphic of doctor and patient side by side
Pharma companies' data sharing around new drug clinical data is on the rise, offering a boost to patient-centricity trustworthiness, a new study finds. (Pixabay)

Pharma companies are learning to share. That is, when it comes to clinical research data, according to findings from the Good Pharma Scorecard biennial ranking.

Now in its third edition, the research found Big Pharma data sharing around clinical research on the upswing, with 95% of patient trials now providing public results within six months of FDA approval. If the time period is extended to 12 months, that improves to 100% for the new drugs reviewed after approval in 2015.

Novo Nordisk and Roche tied for the overall top spot in pharma trial transparency, with perfect scores across trials and data sharing, while Novo Nordisk, Roche, Novartis and Johnson & Johnson all got perfect scores on the data-sharing measurement.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

RELATED: Report cards could be just what pharma needs to get back to respectability

“Patients, industry and all different stakeholder groups are showing real interest in getting data-sharing operationalized across the sector as part of routine clinical research,” said Jennifer Miller, founder of the nonprofit Bioethics International, which compiles the ranking, and an assistant professor at Yale University School of Medicine.

Pharma companies are interested not only for the value of the information itself, but also as a social responsibility tool to “prove” their patient centricity.

“91% of Americans think pharma companies put profits before people. That’s the exact opposite of patient centricity, that’s profit centricity, right?” she said. “So what is their evidence in patient centricity? They have to define that and be able to prove that they’re operationalizing it. The Good Pharma Scorecard is one way of auditing their performance on social responsibility patient centricity.”

Of course, the goal of the scorecard isn’t only to measure data-sharing policies and practices, but also to improve those practices. That was borne out this year when Bioethics gave companies a 30-day window to increase their score. Half of the pharmas in the lower ranks jumped at the chance to improve their scores, showing ranking tools can be useful as a reform strategy, she said.

RELATED: Johnson & Johnson, Sanofi top 'Good Pharma' trial transparency ranking with perfect scores

“They were willing to do it, and I think people might be surprised by that. When I usually give this talk, critics will say, ‘No large multinational company can change policies and practices in 30 days,’ sort of saying, 'This is hopeless, why even try?' But that’s not true at all. At least some of them are willing to change practices to make sure they’re operationalizing and evidencing patient centricity,” Miller said.

There is still room for improvement, of course, as only four out of the 12 pharma companies got perfect data-sharing scores. Another area that could be improved upon is setting and meeting reporting deadlines. While many agree to release research data, they don’t always give a specific date or deadline to file, Miller said.

Suggested Articles

How long can one infusion of Gilead CAR-T drug Yescarta continue to help patients with refractory large B-cell lymphoma? Pretty long, Gilead showed.

AbbVie and Roche have been fielding their fair share of questions about how well their fixed-duration regimen of Venclexta and Rituxan could keep chro

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.